Patient access schemes for high-cost cancer medicines

被引：26
|
作者：
Williamson, Steve [1 ]
机构：
[1] N Tyneside Hosp, Northumbria Healthcare NHS Fdn Trust Pharm, N Shields NE29 8NH, Tyne & Wear, England
来源：
LANCET ONCOLOGY | 2010年 / 11卷 / 02期
关键词：
D O I：
10.1016/S1470-2045(09)70402-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [1] A Shared Drive: Securing Patient Access to High-Cost Medicines
    van der Ent, Leendert
    HEMASPHERE, 2017, 1 (01):
  • [2] Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals
    Hill, Catherine L.
    Pulver, Lisa K.
    Liew, David F. L.
    INTERNAL MEDICINE JOURNAL, 2024,
  • [3] Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund
    Aggarwal, A.
    Fojo, T.
    Chamberlain, C.
    Davis, C.
    Sullivan, R.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 1738 - 1750
  • [4] Approval, reimbursement and pricing of high-cost cancer medicines in Australia
    Agnes Vitry
    Journal of Pharmaceutical Policy and Practice, 8 (Suppl 1)
  • [5] Evaluation of access to high-cost medicines in Australia using national claims data
    Lu, CY
    Williams, K
    Day, R
    VALUE IN HEALTH, 2005, 8 (06) : A28 - A28
  • [6] Identifying stakeholder opinion regarding access to "high-cost medicines": A systematic review of the literature
    Wahlster, Philip
    Scahill, Shane
    Garg, Sanjay
    Babar, Zaheer-Ud-Din
    CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2014, 9 (03): : 513 - 527
  • [7] Targeted access to high-cost medicines in Australia: Early analysis from a qualitative study
    Lu, CY
    Ritchie, J
    Williams, K
    Day, R
    VALUE IN HEALTH, 2005, 8 (06) : A28 - A28
  • [8] Five High-Cost Patient Groups
    Westfall, John M.
    Griswold, Kim
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 (09) : 965 - 965
  • [9] Five High-Cost Patient Groups
    John M. Westfall
    Kim Griswold
    Journal of General Internal Medicine, 2017, 32 : 965 - 965
  • [10] DEFINING A HIGH-COST THRESHOLD FOR MEDICINES AND HOW WAS EXPENDITURE ON HIGH-COST MEDICINES DURING 2018 IN COSTA RICA'S SOCIAL SECURITY SYSTEM (CCSS)
    Marin Piva, H.
    Serrano Madrigal, E.
    Arias Camacho, R.
    VALUE IN HEALTH, 2020, 23 : S292 - S292
12345